VE707

VE707 for prevention of Gram-negative antimicrobial-resistant (AMR) infections

VE707 is our preclinical candidate for the prevention of Gram-negative infections, including those caused by AMR strains, that affect a wide range of vulnerable populations in areas such as oncology, urology, transplantation, and critical care.

VE707 is designed to be administered orally and consists of a defined consortium of commensal bacteria designed to decolonize Gram-negative Enterobacteriaceae, including carbapenem-resistant and extended- spectrum beta-lactamase-producing Klebsiella pneumoniae (Kpn) and Escherichia coli (Eco). We believe among the populations that could potentially benefit from VE707 are patients at high risk for developing life-threatening infections, including those in an intensive care unit, afflicted with blood cancers, with frequent infections such as recurring urinary tract infection (rUTI), and who have received a solid organ transplant or a hematopoietic stem cell transplant, among others.

This program is being advanced with up to $16.6 million of grant funding from CARB-X.